EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

New possibilities for neuroprotection in neonatal hypoxic-ischemic encephalopathy

Suresh Victor, Eridan Rocha-Ferreira, Ahad Rahim, Henrik Hagberg, David Edwards

European Journal of Pediatrics · 2022-03 · 181 (3) · 875-887

DOI: 10.1007/s00431-021-04320-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Pediatrics, online erschienen am 24.11.2021. Verfasst von Suresh Victor und 4 weiteren Autor:innen. Beteiligte Einrichtung: Centre for the Developing Brain, Department of Perinatal Imaging and Health, School of Biomedical Engineering and Imaging Sciences, King's College Lo…. Hauptthemen laut MEDLINE: Hypothermia, Induced, Hypoxia-Ischemia, Brain, Melatonin. Die Arbeit wurde bisher 90-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Around 0.75 million babies worldwide suffer from moderate or severe hypoxic-ischemic encephalopathy (HIE) each year resulting in around 400,000 babies with neurodevelopmental impairment. In 2010, neonatal HIE was associated with 2.4% of the total Global Burden of Disease. Therapeutic hypothermia (TH), a treatment that is now standard of care in high-income countries, provides proof of concept that strategies that aim to improve neurodevelopment are not only possible but can also be implemented to clinical practice. While TH is beneficial, neonates with moderate or severe HIE treated with TH still experience devastating complications: 48% (range: 44–53) combined death or moderate/severe disability. There is a concern that TH may not be effective in low- and middle-income countries. Therapies that further improve outcomes are desperately needed, and in high-income countries, they must be tested in conjunction with TH. We have in this review focussed on pharmacological treatment options (e.g. erythropoietin, allopurinol, melatonin, cannabidiol, exendin-4/exenatide). Erythropoietin and allopurinol show promise and are progressing towards the clinic with ongoing definitive phase 3 randomised placebo-controlled trials. However, there remain global challenges for the next decade. Conclusion : There is a need for more optimal animal models, greater industry support/sponsorship, increased use of juvenile toxicology, dose-ranging studies with pharmacokinetic-pharmacodynamic modelling, and well-designed clinical trials to avoid exposure to harmful medications or abandoning putative treatments. What is Known: • Therapeutic hypothermia is beneficial in neonatal hypoxic-ischemic encephalopathy. • Neonates with moderate or severe hypoxic-ischemic encephalopathy treated with therapeutic hypothermia still experience severe sequelae. What is New: • Erythropoietin, allopurinol, melatonin, cannabidiol, and exendin-4/exenatide show promise in conjunction with therapeutic hypothermia. • There is a need for more optimal animal models, greater industry support/sponsorship, increased use of juvenile toxicology, dose-ranging studies with pharmacokinetic-pharmacodynamic modelling, and well-designed clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypothermia, InducedHypoxia-Ischemia, BrainMelatoninAnimalsHumansHyperplasiaNeuroprotection

Stichwörter der Autor:innen

BrainEncephalopathyHypothermiaInfantNeuroprotectionNewborn

Substanzen

Melatonin

Autor:innen und Institutionen

  • Centre for the Developing Brain, Department of Perinatal Imaging and Health, School of Biomedical Engineering and Imaging Sciences, King's College London, 1st Floor, South Wing, St Thomas' Hospital, Westmister Bridge Ro…
  • Centre for Perinatal Medicine and Health, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • UCL School of Pharmacy, University College London, London, UK.

Förderung

  • Medical Research Council

Zitieren

APA

Victor, S., Rocha-Ferreira, E., Rahim, A., Hagberg, H., & Edwards, D. (2022). New possibilities for neuroprotection in neonatal hypoxic-ischemic encephalopathy. European Journal of Pediatrics, 181(3), 875-887. https://doi.org/10.1007/s00431-021-04320-8

Vancouver

Victor S, Rocha-Ferreira E, Rahim A, Hagberg H, Edwards D. New possibilities for neuroprotection in neonatal hypoxic-ischemic encephalopathy. European Journal of Pediatrics. 2022;181(3):875-887. doi:10.1007/s00431-021-04320-8

BibTeX
@article{Victor2022,
  author = {Victor, Suresh and Rocha-Ferreira, Eridan and Rahim, Ahad and Hagberg, Henrik and Edwards, David},
  title = {New possibilities for neuroprotection in neonatal hypoxic-ischemic encephalopathy},
  journal = {European Journal of Pediatrics},
  year = {2022},
  volume = {181},
  number = {3},
  pages = {875--887},
  doi = {10.1007/s00431-021-04320-8}
}
Kostenlos starten →